Pascal and Francis Bibliographic Databases

Help

Search results

Your search

kw.\*:("PSC 833")

Document Type [dt]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Publication Year[py]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Discipline (document) [di]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Author Country

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Results 1 to 25 of 100

  • Page / 4
Export

Selection :

  • and

New multidrug-resistance-reversing drugs, MS-209 and SDZ PSC 833NAITO, M; TSURUO, T.Cancer chemotherapy and pharmacology. 1997, Vol 40, pp S20-S24, issn 0344-5704, SUPConference Paper

Multidrug resistance modulators PSC 833 and CsA show differential capacity to induce apoptosis in lymphoid leukemia cell lines independently of their MDR phenotypeLOPES, Eloisi C; GARCIA, Mariana; BENAVIDES, Fernando et al.Leukemia research. 2003, Vol 27, Num 5, pp 413-423, issn 0145-2126, 11 p.Article

Cyclosporin A inhibits calcineurin (phosphatase 2B) and P-glycoprotein activity in Entamoeba histolyticaCARRERO, Julio C; LUGO, Haydee; PEREZ, D. Guillermo et al.International journal for parasitology. 2004, Vol 34, Num 9, pp 1091-1097, issn 0020-7519, 7 p.Article

The multidrug resistance modulator SDZ-PSC 833 potentiates the photodynamic activity of chlorin e6 independently of P-glycoprotein in multidrug resistant human breast adenocarcinoma cellsMERLIN, Jean-Louis; GAUTIER, Hervé; BARBERI-HEYOB, Muriel et al.International journal of oncology. 2003, Vol 22, Num 4, pp 733-739, issn 1019-6439, 7 p.Article

Therapeutic approach to Drug resistant tumorsNAITO, M; TSURUO, T.Therapeutic drug monitoring. 1998, Vol 20, Num 5, pp 577-580, issn 0163-4356Conference Paper

Changes in doxorubicin distribution and toxicity in mice pretreated with the cyclosporin analogue SDZ PSC 833GONZALEZ, O; COLOMBO, T; DE FUSCO, M et al.Cancer chemotherapy and pharmacology. 1995, Vol 36, Num 4, pp 335-340, issn 0344-5704Article

Role of lipoproteins in the plasma binding of SDZ PSC 833, a novel multidrug resistance-reversing cyclosporinSIMON, N; DAILLY, E; COMBES, O et al.British journal of clinical pharmacology. 1998, Vol 45, Num 2, pp 173-175, issn 0306-5251Article

Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin ATWENTYMAN, P. R; BLEEHEN, N. M.European journal of cancer (1990). 1991, Vol 27, Num 12, pp 1639-1642, issn 0959-8049Article

Development of a liquid chromatography-mass spectrometry (LC/MS) assay method for the quantification of PSC 833 (Valspodar) in rat plasmaBINKHATHLAN, Ziyad; SOMAYAJI, Vishwa; BROCKS, Dion R et al.Journal of chromatography. B. 2008, Vol 869, Num 1-2, pp 31-37, issn 1570-0232, 7 p.Article

HPLC method for monitoring SDZ PSC 833 in whole bloodSCOTT, M. G; HOCK, K. G; CRIMMINS, D. L et al.Clinical chemistry (Baltimore, Md.). 1997, Vol 43, Num 3, pp 505-510, issn 0009-9147Article

Reversal of typical multidrug resistance by cyclosporin and its non-immunosuppressive analogue SDZ PSC 833 in Chinese hamster ovary cells expressing the mdr1 phenotypeTE BOEKHORST, P. A. W; VAN KAPEL, J; SCHOESTER, M et al.Cancer chemotherapy and pharmacology. 1992, Vol 30, Num 3, pp 238-242, issn 0344-5704Article

Development of a polymeric micellar formulation for valspodar and assessment of its pharmacokinetics in ratBINKHATHLAN, Ziyad; HAMDY, Dalia A; BROCKS, Dion R et al.European journal of pharmaceutics and biopharmaceutics. 2010, Vol 75, Num 2, pp 90-95, issn 0939-6411, 6 p.Article

Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (valspodar)ADVANI, R; SABA, H. I; PAIETTA, E et al.Blood. 1999, Vol 93, Num 3, pp 787-795, issn 0006-4971Article

Comparison of cyclosporin A and SDZ PSC833 as multidrug-resistance modulators in a daunorubicin-resistant Ehrlich ascites tumorFRICHE, E; JENSEN, P. B; NISSEN, N. I et al.Cancer chemotherapy and pharmacology. 1992, Vol 30, Num 3, pp 235-237, issn 0344-5704Article

Effect of PSC 833, a potent inhibitor of P-glycoprotein, on the growth of astrocytoma cells in vitroSADANAND, V; KANKESAN, J; YUSUF, A et al.Cancer letters. 2003, Vol 198, Num 1, pp 21-27, issn 0304-3835, 7 p.Article

Potential roles of P-gp and calcium channels in loperamide and diphenoxylate transportCROWE, Andrew; WONG, Penny.Toxicology and applied pharmacology. 2003, Vol 193, Num 1, pp 127-137, issn 0041-008X, 11 p.Article

PSC 833 modulation of Multidrug resistance to paclitaxel in cultured human ovarian carcinoma cells leads to apoptosisDURAJ, Jozef; SEDLAK, Jan; BIES, Juraj et al.Anticancer research. 2002, Vol 22, Num 6A, pp 3425-3428, issn 0250-7005, 4 p.Article

Potential role of acid ceramidase in conversion of cytostatic to cytotoxic end-point in pancreatic cancer cellsMORAD, Samy A. F; MESSNER, Maria C; LEVIN, Jonathan C et al.Cancer chemotherapy and pharmacology. 2013, Vol 71, Num 3, pp 635-645, issn 0344-5704, 11 p.Article

Effect of PSC 833, an inhibitor of P-glycoprotein, on 1,2-dimethylhydrazine-induced liver carcinogenesis in ratsKANKESAN, Janarthanan; YUSUF, Aroon; LACONI, Ezio et al.Carcinogenesis (New York. Print). 2003, Vol 24, Num 12, pp 1977-1984, issn 0143-3334, 8 p.Article

Effects of the novel cyclosporine derivative PSC833 on glucose metabolism in rat primary cultures of neuronal and glial cellsCRUZ, Fatima; WOLF, Armin.Biochemical pharmacology. 2001, Vol 62, Num 1, pp 129-139, issn 0006-2952Article

Dose-dependent effects of PSC 833 on its tissue distribution and on the biliary excretion of endogenous substrates in ratsSONG, S; SUZUKI, H; KAWAI, R et al.Drug metabolism and disposition. 1998, Vol 26, Num 11, pp 1128-1133, issn 0090-9556Article

Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833VAN ASPEREN, J; VAN TELLINGEN, O; SPARREBOOM, A et al.British journal of cancer. 1997, Vol 76, Num 9, pp 1181-1183, issn 0007-0920Article

Disruption of mitochondrial membrane potential during apoptosis induced by PSC 833 and CsA in multidrug-resistant lymphoid leukemiaBUSTAMANTE, Juanita; LOPES, Eloisi Caldas; GARCIA, Mariana et al.Toxicology and applied pharmacology. 2004, Vol 199, Num 1, pp 44-51, issn 0041-008X, 8 p.Article

Cytotoxic activity of cyclosporin A and [3-keto-Bmt1]-[Val2]-cyclosporin (SDZ PSC 833) on tumour cells from patients with haematological malignanciesMARTINSSON, P; NYGREN, P; FRIDBORG, H et al.European journal of clinical pharmacology. 1997, Vol 52, Num 3, pp 199-203, issn 0031-6970Article

Inhibition of P-glycoprotein-mediated vinblastine transport across HCT-8 intestinal carcinoma monolayers by verapamil cyclosporine A and SDZ PSC 833 in dependence on extracellular pHZACHERL, J; HAMILTON, G; WENZL, E et al.Cancer chemotherapy and pharmacology. 1994, Vol 34, Num 2, pp 125-132, issn 0344-5704Article

  • Page / 4